Pages that link to "Q55035623"
Jump to navigation
Jump to search
The following pages link to Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. (Q55035623):
Displaying 50 items.
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acids (Q24624489) (← links)
- Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs) (Q26768654) (← links)
- Antibody-drug conjugates--an emerging class of cancer treatment (Q26770312) (← links)
- Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis (Q26772873) (← links)
- The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia (Q26783425) (← links)
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics (Q26800175) (← links)
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin (Q27009160) (← links)
- Antibody Drug Conjugates: Preclinical Considerations (Q27022321) (← links)
- Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells (Q28236669) (← links)
- The evolving role of natural products in drug discovery (Q28236671) (← links)
- Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry (Q28544658) (← links)
- Cell and tumor classification using gene expression data: construction of forests (Q30777888) (← links)
- Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia (Q33248188) (← links)
- Development of a small peptide tag for covalent labeling of proteins (Q33289409) (← links)
- Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). (Q33343994) (← links)
- Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas (Q33361455) (← links)
- Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence (Q33368039) (← links)
- Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab (Q33405150) (← links)
- The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice. (Q33673059) (← links)
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity (Q34192806) (← links)
- Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies (Q34276476) (← links)
- Arming antibodies: prospects and challenges for immunoconjugates (Q34449555) (← links)
- Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. (Q34565264) (← links)
- B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response (Q34819635) (← links)
- Protein conjugation with genetically encoded unnatural amino acids (Q34838057) (← links)
- Glycosyloxyamine neoglycosylation: a model study using calicheamicin. (Q34847872) (← links)
- Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse (Q35007569) (← links)
- Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities (Q35058921) (← links)
- Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development (Q35105725) (← links)
- New developments in antibody therapy for acute myeloid leukemia (Q35206364) (← links)
- Treatment concepts for elderly patients with acute myeloid leukemia. (Q35291847) (← links)
- Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components (Q35459059) (← links)
- Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells (Q35626517) (← links)
- Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress (Q35674386) (← links)
- Use of fluorine in the medicinal chemistry and chemical biology of bioactive compounds--a case study on fluorinated taxane anticancer agents (Q35762544) (← links)
- Emerging treatments in acute myeloid leukaemia (Q35779278) (← links)
- Using antibodies in tumour immunotherapy (Q35842612) (← links)
- Human leukaemic stem cells: a novel target of therapy. (Q35854964) (← links)
- Tumour-targeted chemotherapy with immunoconjugates of calicheamicin (Q35873771) (← links)
- CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance (Q35980938) (← links)
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy (Q36058588) (← links)
- Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies (Q36200153) (← links)
- Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products (Q36273796) (← links)
- Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia (Q36304822) (← links)
- Antibody-cytotoxic agent conjugates for cancer therapy (Q36316831) (← links)
- Recent advances in targeted therapy of human myelogenous leukaemia (Q36318531) (← links)
- Development of antibodies and chimeric molecules for cancer immunotherapy (Q36490753) (← links)
- Leukemia stem cells. (Q36574172) (← links)
- Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum (Q36899294) (← links)
- Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin (Q36932014) (← links)